留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

炎症性肠病妊娠期管理的专家共识意见

中华医学会消化病学分会炎症性肠病学组

中华医学会消化病学分会炎症性肠病学组. 炎症性肠病妊娠期管理的专家共识意见[J]. 协和医学杂志, 2019, 10(5): 465-475. doi: 10.3969/j.issn.1674-9081.2019.05.008
引用本文: 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病妊娠期管理的专家共识意见[J]. 协和医学杂志, 2019, 10(5): 465-475. doi: 10.3969/j.issn.1674-9081.2019.05.008

炎症性肠病妊娠期管理的专家共识意见

doi: 10.3969/j.issn.1674-9081.2019.05.008
基金项目: 

卫生部行业专项基金 201002020

国家支撑项目基金 2015BA13B07

中国医学科学院医学与健康科技创新工程 2016-I2M-3-001

详细信息
    通讯作者:

    钱家鸣, E-mail:qianjiaming1957@126.com

  • 中图分类号: R574.1;R714

  • 摘要: 炎症性肠病大多于中青年发病, 会面临生育问题, 故加强妊娠前咨询、优化妊娠期管理可改善不良妊娠结局, 提高患者生命质量。本共识基于循证医学依据和Delphi方法, 在妊娠前指导和管理、妊娠期管理、分娩方式、哺乳期管理和婴儿疫苗接种共5个方面达成初步共识, 为临床工作提供指导。
    利益冲突  无
  • 表  1  炎症性肠病患者常用药物在妊娠期和哺乳期的用药风险

    药物 妊娠期用药风险 哺乳期用药风险
    美沙拉秦 低风险 低风险
    柳氮磺吡啶 低风险 慎用
    糖皮质激素 低风险 低风险
    硫唑嘌呤 低风险 慎用(有争议)
    抗肿瘤坏死因子α单克隆抗体 低风险 低风险
    维多珠单克隆抗体 未知 未知
    甲氨蝶呤 禁用 禁用
    沙利度胺 禁用 禁用
    环孢素 慎用 禁用
    下载: 导出CSV
  • [1] Martin L, Peche W, Peterson K, et al.Population Based Paternity Rate and Partner Birth Outcomes Among Utah Men With Inflammatory Bowel Disease[J]. Am J Gastroenterol, 2017, 112:1722-1727. doi:  10.1038/ajg.2017.279
    [2] Tavernier N, Fumery M, Peyrin-Biroulet L, et al.Systematic review:fertility in non-surgically treated inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2013, 38:847-853. doi:  10.1111/apt.12478
    [3] Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn's disease:a case control study by European collaborative group[J]. Gut, 1986, 27:821-825. doi:  10.1136/gut.27.7.821
    [4] Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2007, 13:591-599. doi:  10.1002/ibd.20082
    [5] Ording Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis:female fecundity before diagnosis, during disease, and after surgery compared with a population sample[J]. Gastroenterology, 2002, 122:15-19. doi:  10.1053/gast.2002.30345
    [6] Waljee A. Waljee J, Morris AM, et al. Threefold increased risk of infertility:a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis[J]. Gut, 2006, 55:1575-1580. doi:  10.1136/gut.2005.090316
    [7] Rajaratnam SG, Eglinton TW, Hider P, et al.Impact of ileal pouch-anal anastomosis on female fertility:meta-analysis and systematic review[J]. Int J Colorectal Dis, 2011, 26:1365-1374. doi:  10.1007/s00384-011-1274-9
    [8] Ananthakrishnan AN, Martin C, Kane S, et al. Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases[J]. Clin Gastroenterol Hepatol, 2019, 17:203-204. doi:  10.1016/j.cgh.2018.04.001
    [9] Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease[J]. N Engl J Med, 1991, 324:84-88. doi:  10.1056/NEJM199101103240203
    [10] Peeters M, Nevens H, Baert F, et al. Familial aggregation in Crohn's disease:increased age-adjusted risk and concordance in clinical characteristics[J]. Gastroenterology, 1996, 111:597-603. doi:  10.1053/gast.1996.v111.pm8780562
    [11] Jolving LR, Nielsen J, Beck-Nielsen SS, et al. The Association Between Maternal Chronic Inflammatory Bowel Disease and Long-term Health Outcomes in Children-A Nationwide Cohort Study[J]. Inflamm Bowel Dis, 2017, 23:1440-1446. doi:  10.1097/MIB.0000000000001146
    [12] Orholm M, Fonager K, Sorensen HT. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease[J]. Am J Gastroenterol, 1999, 94:3236-3238. doi:  10.1111/j.1572-0241.1999.01526.x
    [13] Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease[J]. Gastroenterology, 1991, 100:1638-1643. doi:  10.1016/0016-5085(91)90663-6
    [14] Laharie D, Debeugny S, Peeters M, et al.Inflammatory bowel disease in spouses and their offspring[J]. Gastroenterology, 2001, 120:816-819. doi:  10.1053/gast.2001.22574
    [15] Julsgaard M, Norgaard M, Hvas CL, et al.Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis[J]. Inflamm Bowel Dis, 2011, 17:1573-1580. doi:  10.1002/ibd.21522
    [16] Nielsen MJ, Norgaard M, Holland-Fisher P, et al.Self-reported antenatal adherence to medical treatment among pregnant women with Crohn's disease[J]. Aliment Pharmacol Ther, 2010, 32:49-58. doi:  10.1111/j.1365-2036.2010.04318.x
    [17] de Lima A, Zelinkova Z, Mulders AG, et al. Preconception Care Reduces Relapse of Inflammatory Bowel Disease During Pregnancy[J]. Clin Gastroenterol Hepatol, 2016, 14:1285-1292.e1. doi:  10.1016/j.cgh.2016.03.018
    [18] Mountifield R, Andrews JM, Bampton P.It is worth the effort:Patient knowledge of reproductive aspects of inflammatory bowel disease improves dramatically after a single group education session[J]. J Crohns Colitis, 2014, 8:796-801. doi:  10.1016/j.crohns.2013.12.019
    [19] Reddy D, Murphy SJ, Kane SV, et al.Relapses of inflammatory bowel disease during pregnancy:in-hospital management and birth outcomes[J]. Am J Gastroenterol, 2008, 103:1203-1209. doi:  10.1111/j.1572-0241.2007.01756.x
    [20] Pedersen N, Bortoli A, Duricova D, et al. The course of inflammatory bowel disease during pregnancy and postpartum:a prospective European ECCO-EpiCom Study of 209 pregnant women[J]. Aliment Pharmacol Ther, 2013, 38:501-512. doi:  10.1111/apt.12412
    [21] Miller JP.Inflammatory bowel disease in pregnancy:a review[J]. J R Soc Med, 1986, 79:221-225. doi:  10.1177/014107688607900410
    [22] Bengtson MB, Solberg IC, Aamodt G, et al. Relationships between inflammatory bowel disease and perinatal factors:both maternal and paternal disease are related to preterm birth of offspring[J]. Inflamm Bowel Dis, 2010, 16:847-855. doi:  10.1002/ibd.21120
    [23] Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease:a large community-based study from Northern California[J]. Gastroenterology, 2007, 133:1106-1112. doi:  10.1053/j.gastro.2007.07.019
    [24] Naganuma M, Kunisaki R, Yoshimura N, et al. Conception and pregnancy outcome in women with inflammatory bowel disease:A multicentre study from Japan[J]. J Crohns Colitis, 2011, 5:317-323. doi:  10.1016/j.crohns.2011.02.003
    [25] Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden[J]. Inflamm Bowel Dis, 2011, 17:795-801. doi:  10.1002/ibd.21369
    [26] Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy[J]. Gut, 2007, 56:830-837. doi:  10.1136/gut.2006.108324
    [27] Lin HC, Chiu CC, Chen SF, et al. Ulcerative colitis and pregnancy outcomes in an Asian population[J]. Am J Gastroenterol, 2010, 105:387-394. doi:  10.1038/ajg.2009.562
    [28] Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease:prospective European case-control ECCO-EpiCom study, 2003-2006[J]. Aliment Pharmacol Ther, 2011, 34:724-734. doi:  10.1111/j.1365-2036.2011.04794.x
    [29] Ito A, Iizuka B, Omori T, et al.Relationship between the Clinical Course of Ulcerative Colitis during Pregnancy and the Outcomes of Pregnancy:A Retrospective Evaluation[J]. Intern Med, 2018, 57:159-164. doi:  10.2169/internalmedicine.8550-16
    [30] Ujihara M, Ando T, Ishiguro K, et al. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis[J]. BMC Res Notes, 2013, 6:210. doi:  10.1186/1756-0500-6-210
    [31] Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospita-lized ulcerative colitis:the Toronto consensus[J]. Gastroenterology, 2015, 148:1035-1058.e3. doi:  10.1053/j.gastro.2015.03.001
    [32] Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases:a systematic review[J]. Gut, 2012, 61:1619-1635. doi:  10.1136/gutjnl-2012-302830
    [33] Hanan IM. Inflammatory bowel disease in the pregnant woman[J]. Compr Ther, 1998, 24:409-414.
    [34] Kelley KE, Hernandez-Diaz S, Chaplin EL, et al. Identification of phthalates in medications and dietary supplement formulations in the United States and Canada[J]. Environ Health Perspect, 2012, 120:379-384. doi:  10.1289/ehp.1103998
    [35] Hernandez-Diaz S, Su YC, Mitchell AA, et al.Medications as a potential source of exposure to phthalates among women of childbearing age[J]. Reprod Toxicol, 2013, 37:1-5. doi:  10.1016/j.reprotox.2013.01.001
    [36] Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis[J]. Arthritis Rheum, 2008, 58:3299-3308. doi:  10.1002/art.24034
    [37] Dara P, Slater LM, Armentrout SA.Successful pregnancy during chemotherapy for acute leukemia[J]. Cancer, 1981, 47:845-846. doi:  10.1002/1097-0142(19810301)47:5<845::AID-CNCR2820470504>3.0.CO;2-4
    [38] Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al.Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease[J]. Am J Med, 1990, 88:589-592. doi:  10.1016/0002-9343(90)90522-F
    [39] Martinez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding)[J]. Clin Exp Rheumatol, 2009, 27:678-684. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b3b901f6691248c0e24c99182e1f4c78
    [40] Hernandez-Diaz S, Werler MM, Walker AM, et al.Folic acid antagonists during pregnancy and the risk of birth defects[J]. N Engl J Med, 2000, 343:1608-1614. doi:  10.1056/NEJM200011303432204
    [41] Smithells RW, Newman CG. Recognition of thalidomide defects[J]. J Med Genet, 1992, 29:716-723. doi:  10.1136/jmg.29.10.716
    [42] Peng X, Zhi M, Wei M, et al. Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients[J]. Medicine (Baltimore), 2017, 96:e6540. doi:  10.1097/MD.0000000000006540
    [43] O'Morain C, Smethurst P, Dore CJ, et al. Reversible male infertility due to sulphasalazine:studies in man and rat[J]. Gut, 1984, 25:1078-1784. doi:  10.1136/gut.25.10.1078
    [44] Mahadevan U, Terdiman JP, Aron J, et al. Infliximab and semen quality in men with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2005, 11:395-399. doi:  10.1097/01.MIB.0000164023.10848.c4
    [45] Villiger PM, Caliezi G, Cottin V, et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis[J]. Ann Rheum Dis, 2010, 69:1842-1844. doi:  10.1136/ard.2009.127423
    [46] Teruel C, Lopez-San Roman A, Bermejo F, et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines[J]. Am J Gastroenterol, 2010, 105:2003-2008. doi:  10.1038/ajg.2010.138
    [47] Dejaco C, Mittermaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease[J]. Gastroenterology, 2001, 121:1048-1053. doi:  10.1053/gast.2001.28692
    [48] Norgard B, Czeizel AE, Rockenbauer M, et al. Population-based case control study of the safety of sulfasalazine use during pregnancy[J]. Aliment Pharmacol Ther, 2001, 15:483-486. doi:  10.1046/j.1365-2036.2001.00962.x
    [49] Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs:a meta-analysis[J]. Reprod Toxicol, 2008, 25:271-275. doi:  10.1016/j.reprotox.2007.11.010
    [50] Norgard B, Fonager K, Pedersen L, et al.Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy:a Danish cohort study[J]. Gut, 2003, 52:243-237. doi:  10.1136/gut.52.2.243
    [51] Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2013, 19:15-22. doi:  10.1002/ibd.22948
    [52] Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines:cohort from the CESAME Study[J]. Gut, 2011, 60:198-203. doi:  10.1136/gut.2010.222893
    [53] Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease[J]. Am J Gastroenterol, 2013, 108:433-440. doi:  10.1038/ajg.2012.430
    [54] Langagergaard V, Pedersen L, Gislum M, et al. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy:A Danish nationwide cohort study[J]. Aliment Pharmacol Ther, 2007, 25:73-81.
    [55] Kanis SL, de Lima-Karagiannis A, de Boer NKH, et al. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study[J]. Clin Gastroenterol Hepatol, 2017, 15:1232-1241.e1. doi:  10.1016/j.cgh.2017.02.041
    [56] Kane SV, Acquah LA. Placental transport of immunoglobulins:a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy[J]. Am J Gastroenterol, 2009, 104:228-233. doi:  10.1038/ajg.2008.71
    [57] Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease[J]. Clin Gastroenterol Hepatol, 2013, 11:286-292, e24. doi:  10.1016/j.cgh.2012.11.011
    [58] Cheent K, Nolan J, Shariq S, et al. Case Report:Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease[J]. J Crohns Colitis, 2010, 4:603-605. doi:  10.1016/j.crohns.2010.05.001
    [59] Mahadevan U, Martin CF, Sandler RS, et al. PIANO:a 1000 patient prospective registry of pregnancy outcomes in women with ibd exposed to immunomodulators and biologic therapy[J]. Gastroenterology, 2012, 142:S149.
    [60] Julsgaard M, Kjeldsen J, Baumgart DC.Vedolizumab safety in pregnancy and newborn outcomes[J]. Gut, 2017, 66:1866-1867. doi:  10.1136/gutjnl-2016-313444
    [61] Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy:outcomes from clinical studies in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2017, 45:941-950. doi:  10.1111/apt.13960
    [62] Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids:prospective cohort study and meta-analysis of epidemiological studies[J]. Teratology, 2000, 62:385-392. doi:  10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z
    [63] Hviid A, Molgaard-Nielsen D.Corticosteroid use during pregnancy and risk of orofacial clefts[J]. Cmaj, 2011, 183:796-804. doi:  10.1503/cmaj.101063
    [64] Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension:nested case-control study[J]. BMJ, 2005, 330:230. doi:  10.1136/bmj.38313.624352.8F
    [65] Bar Oz B, Hackman R, Einarson T, et al.Pregnancy outcome after cyclosporine therapy during pregnancy:a meta-analysis[J]. Transplantation, 2001, 71:1051-1055. doi:  10.1097/00007890-200104270-00006
    [66] Branche J, Cortot A, Bourreille A, et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy[J]. Inflamm Bowel Dis, 2009, 15:1044-1048. doi:  10.1002/ibd.20858
    [67] Piper JM, Mitchel EF, Ray WA.Prenatal use of metronidazole and birth defects:no association[J]. Obstet Gynecol, 1993, 82:348-352.
    [68] Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes[J]. Antimicrob Agents Chemother, 2012, 56:4800-4805. doi:  10.1128/AAC.06477-11
    [69] Linseman DA, Hampton LA, Branstetter DG. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin[J]. Fundam Appl Toxicol, 1995, 28:59-64. doi:  10.1006/faat.1995.1146
    [70] Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease:a population-based cohort study[J]. Thromb Haemost, 2001, 85:430-434. doi:  10.1055/s-0037-1615600
    [71] Pomp ER, Lenselink AM, Rosendaal FR, et al. Pregnancy, the postpartum period and prothrombotic defects:risk of venous thrombosis in the MEGA study[J]. J Thromb Haemost, 2008, 6:632-637. doi:  10.1111/j.1538-7836.2008.02921.x
    [72] 中华医学会消化病学分会炎症性肠病学组.中国住院炎症性肠病患者静脉血栓栓塞症防治的专家共识意见[J].中华炎性肠病杂志, 2018, 2:75-82. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyxcbzz201802002
    [73] Killeen S, Gunn J, Hartley J. Surgical management of complicated and medically refractory inflammatory bowel disease during pregnancy[J]. Colorectal Dis, 2017, 19:123-138. doi:  10.1111/codi.13413
    [74] Panes J, Bouzas R, Chaparro M, et al. Systematic review:the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease[J]. Aliment Pharmacol Ther, 2011, 34:125-145. doi:  10.1111/j.1365-2036.2011.04710.x
    [75] Schreyer AG, Menzel C, Friedrich C, et al. Comparison of high-resolution ultrasound and MR-enterography in patients with inflammatory bowel disease[J]. World J Gastroenterol, 2011, 17:1018-1025. https://www.ncbi.nlm.nih.gov/pubmed/21448353
    [76] Stern MD, Kopylov U, Ben-Horin S, et al. Magnetic resonance enterography in pregnant women with Crohn's disease:case series and literature review[J]. BMC Gastroenterol, 2014, 14:146. doi:  10.1186/1471-230X-14-146
    [77] Birchard KR, Brown MA, Hyslop WB, et al. MRI of acute abdominal and pelvic pain in pregnant patients[J]. AJR Am J Roentgenol, 2005, 184:452-458. doi:  10.2214/ajr.184.2.01840452
    [78] Tremblay E, Therasse E, Thomassin-Naggara I, et al. Quality initiatives:guidelines for use of medical imaging during pregnancy and lactation[J]. Radiographics, 2012, 32:897-911. doi:  10.1148/rg.323115120
    [79] Schulze H, Esters P, A Dignass.Review article:the management of Crohn's disease and ulcerative colitis during pregnancy and lactation[J]. Aliment Pharmacol Ther, 2014, 40:991-1008. doi:  10.1111/apt.12949
    [80] Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy[J]. Gastroenterology, 2016, 150:734-757.e1. doi:  10.1053/j.gastro.2015.12.003
    [81] van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease[J]. J Crohns Colitis, 2015, 9:107-124. doi:  10.1093/ecco-jcc/jju006
    [82] Shergill AK, Ben-Menachem T, Chandrasekhara V, et al. Guidelines for endoscopy in pregnant and lactating women[J]. Gastrointest Endosc, 2012, 76:18-24. doi:  10.1016/j.gie.2012.02.029
    [83] Ludvigsson JF, Lebwohl B, Ekbom A, et al. Outcomes of Pregnancies for Women Undergoing Endoscopy While They Were Pregnant:A Nationwide Cohort Study[J]. Gastroenterology, 2017, 152:554-563.e9. doi:  10.1053/j.gastro.2016.10.016
    [84] De Lima A, Galjart B, Wisse PH, et al. Does lower gastrointestinal endoscopy during pregnancy pose a risk for mother and child?-a systematic review[J]. BMC Gastroenterol, 2015, 15:15. doi:  10.1186/s12876-015-0244-z
    [85] Abdul Sultan A, West J, Ban L, et al. Adverse Pregnancy Outcomes Among Women with Inflammatory Bowel Disease:A Population-Based Study from England[J]. Inflamm Bowel Dis, 2016, 22:1621-1630. doi:  10.1097/MIB.0000000000000802
    [86] Foulon A, Dupas JL, Sabbagh C, et al. Defining the Most Appropriate Delivery Mode in Women with Inflammatory Bowel Disease:A Systematic Review[J]. Inflamm Bowel Dis, 2017, 23:712-720. doi:  10.1097/MIB.0000000000001112
    [87] Ananthakrishnan AN, Cheng A, Cagan A, et al. Mode of childbirth and long-term outcomes in women with inflammatory bowel diseases[J]. Dig Dis Sci, 2015, 60:471-477. doi:  10.1007/s10620-014-3353-6
    [88] Grouin A, Brochard C, Siproudhis L, et al. Perianal Crohn's disease results in fewer pregnancies but is not exacerbated by vaginal delivery[J]. Dig Liver Dis, 2015, 47:1021-1026. doi:  10.1016/j.dld.2015.08.001
    [89] McConnell RA, Mahadevan U.Pregnancy and the Patient with Inflammatory Bowel Disease:Fertility, Treatment, Delivery, and Complications[J]. Gastroenterol Clin North Am, 2016, 45:285-301. doi:  10.1016/j.gtc.2016.02.006
    [90] Burke KE, Haviland MJ, Hacker MR, et al. Indications for Mode of Delivery in Pregnant Women with Inflammatory Bowel Disease[J]. Inflamm Bowel Dis, 2017, 23:721-726. doi:  10.1097/MIB.0000000000001113
    [91] Smink M, Lotgering FK, Albers L, et al. Effect of childbirth on the course of Crohn's disease; results from a retrospective cohort study in the Netherlands[J]. BMC Gastroenterol, 2011, 11:6. doi:  10.1186/1471-230X-11-6
    [92] Bernstein CN, Banerjee A, Targownik LE, et al. Cesarean Section Delivery Is Not a Risk Factor for Development of Inflammatory Bowel Disease:A Population-based Analysis[J]. Clin Gastroenterol Hepatol, 2016, 14:50-57. doi:  10.1016/j.cgh.2015.08.005
    [93] Mahadevan U, McConnell RA, Chambers CD. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease[J]. Gastroenterology, 2017, 152:451-462.e2. doi:  10.1053/j.gastro.2016.10.013
    [94] Branski D, Kerem E, Gross-Kieselstein E, et al. Bloody diarrhea-a possible complication of sulfasalazine transferred through human breast milk[J]. J Pediatr Gastroenterol Nutr, 1986, 5:316-317. doi:  10.1097/00005176-198605020-00028
    [95] Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease:Special situations[J]. J Crohns Colitis, 2010, 4:63-101. doi:  10.1016/j.crohns.2009.09.009
    [96] Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy[J]. Expert Rev Clin Immunol, 2013, 9:161-73; quiz 174.
    [97] Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation[J]. Aliment Pharmacol Ther, 2008, 28:1209-1213. doi:  10.1111/j.1365-2036.2008.03843.x
    [98] Sau A, Clarke S, Bass J, et al. Azathioprine and breastfeeding:is it safe?[J]. BJOG, 2007, 114:498-501. doi:  10.1111/j.1471-0528.2006.01232.x
    [99] Sammaritano LR, Bermas BL.Rheumatoid arthritis medications and lactation[J]. Curr Opin Rheumatol, 2014, 26:354-360. doi:  10.1097/BOR.0000000000000055
    [100] Moretti ME, Verjee Z, Ito S, et al. Breast-feeding during maternal use of azathioprine[J]. Ann Pharmacother, 2006, 40:2269-2272. doi:  10.1345/aph.1H152
    [101] Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation[J]. Ann Rheum Dis, 2016, 75:795-810. doi:  10.1136/annrheumdis-2015-208840
    [102] Zelinkova Z, De Boer IP, Van Dijke MJ, et al. Azathioprine treatment during lactation[J]. Aliment Pharmacol Ther, 2009. 30: 90-91; author reply 91.
    [103] Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation[J]. Nat Rev Gastroenterol Hepatol, 2014, 11:116-127. doi:  10.1038/nrgastro.2013.135
    [104] Niebyl JR.Antibiotics and other anti-infective agents in pregnancy and lactation[J]. Am J Perinatol, 2003, 20:405-414. doi:  10.1055/s-2003-45391
    [105] WHO. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans: Vol. 50 Pharmaceutical Drugs[M].Lyon: International Agency for Research on Cancer, 1990: 77-114.
    [106] Yamada T, Mogi M, Kage T, et al. Enhancement by cyclosporin A of metastasis from hamster cheek pouch carcinoma[J]. Arch Oral Biol, 1992, 37:593-596. doi:  10.1016/0003-9969(92)90143-V
    [107] Pistilli B, Bellettini G, Giovannetti E, et al. Chemo-therapy, targeted agents, antiemetics and growth-factors in human milk:how should we counsel cancer patients about breastfeeding?[J]. Cancer Treat Rev, 2013, 39:207-211. doi:  10.1016/j.ctrv.2012.10.002
    [108] Johns DG, Rutherford LD, Leighton PC, et al. Secretion of methotrexate into human milk[J]. Am J Obstet Gynecol, 1972, 112:978-980. doi:  10.1016/0002-9378(72)90824-1
    [109] Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregn-ancy and breast-feeding[J]. Inflamm Bowel Dis, 2010, 16:881-895. doi:  10.1002/ibd.21154
    [110] Morton A. Cyclosporine and lactation[J]. Nephrology (Carlton), 2011, 16:249.
    [111] Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease[J]. J Crohns Colitis, 2011, 5:555-558. doi:  10.1016/j.crohns.2011.05.006
    [112] Kattah MG, Milush JM, Burt T, et al. Anti-TNF and thiopurine therapy in pregnant IBD patients does not signi-ficantly alter a panel of B-cell and T-cell subsets in 1-year-old infants[J]. Clin Transl Gastroenterol, 2018, 9:143. doi:  10.1038/s41424-018-0018-3
    [113] Esteve-Sole A, Deya-Martinez A, Teixido I, et al. Immunological Changes in Blood of Newborns Exposed to Anti-TNF-alpha during Pregnancy[J]. Front Immunol, 2017, 8:1123. doi:  10.3389/fimmu.2017.01123
    [114] Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection[J]. Gastroenterology, 2016, 151:110-119. doi:  10.1053/j.gastro.2016.04.002
    [115] Wieringa JW, Driessen GJ, Van Der Woude CJ.Pregnant women with inflammatory bowel disease:the effects of biologicals on pregnancy, outcome of infants, and the developing immune system[J]. Expert Rev Gastroenterol Hepatol, 2018, 12:811-818. doi:  10.1080/17474124.2018.1496820
  • 加载中
表(1)
计量
  • 文章访问数:  317
  • HTML全文浏览量:  85
  • PDF下载量:  396
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-08-19
  • 刊出日期:  2019-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!